unknown
Stage
1
Investors
About
Genepredict lance Melapred Access, l\'examen clinico-génétique de stratification du risque de mélanome. Validé sur 5 200 individus.
Explore GENEPRED's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.